青年起病2型糖尿病血糖控制的循环代谢物生物标志物
研究在TODAY研究中测量393名10-17岁青年起病2型糖尿病患者的480种空腹血浆代谢物,随机接受二甲双胍、二甲双胍联合罗格列酮或二甲双胍联合生活方式干预。中位12.4个月内179人血糖控制丧失,33种基线代谢物与血糖控制丧失相关,己糖和呫吨酸与治疗失败的关联因治疗分组而异。
要点
- 在TODAY研究中,179/393名青年起病2型糖尿病患者发生血糖控制丧失(HbA1c≥8%或需胰岛素治疗),平均随访12.4个月。
- 33种基线代谢物与血糖控制丧失相关(q<0.05);己糖和呫吨酸与治疗失败的关联因随机治疗组而异。
- d-葡萄糖酸和1,5-AG/1-脱氧葡萄糖的变化预测治疗失败优于HbA1c或β细胞功能指标的变化。
核心结论
- 代谢组学可揭示与青年起病2型糖尿病血糖控制丧失相关的循环小分子,并可能提示导致治疗失败的代谢通路。
研究设计与样本
- 在TODAY研究中测量393名10-17岁青年起病2型糖尿病患者的480种空腹血浆代谢物,随机分为二甲双胍、二甲双胍联合罗格列酮或二甲双胍联合生活方式干预三组。
- 304名参与者在36个月后获得额外代谢组学测量。
- 采用Cox模型评估基线代谢物、代谢物与治疗组的交互作用以及0-36个月代谢物变化与血糖控制丧失的关联,调整年龄、性别、种族、治疗组和BMI。
- 使用弹性网回归生成血糖失败的代谢物预测模型,并与临床危险因素比较。
主要发现
- 393名参与者中179名发生血糖控制丧失(HbA1c≥8%或胰岛素治疗),平均12.4个月。
- 33种基线代谢物水平与血糖控制丧失相关(q<0.05)。
- 己糖和呫吨酸与治疗失败的关联因随机治疗组而异;基线水平较高的青年在二甲双胍单药治疗下治疗失败风险较低。
- 3种代谢物0-36个月的变化与血糖控制丧失相关(q<0.05)。
- d-葡萄糖酸和1,5-AG/1-脱氧葡萄糖的变化预测治疗失败优于HbA1c或β细胞功能指标的变化,而所测代谢物的基线水平则无此优势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to identify metabolites associated with loss of glycemic control in youth-onset type 2 diabetes. RESEARCH DESIGN AND METHODS: We measured 480 metabolites in fasting plasma samples from the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study. Participants (N = 393; age 10-17 years) were randomly assigned to metformin, metformin plus rosiglitazone, or metformin plus lifestyle intervention. Additional metabolomic measurements after 36 months were obtained in 304 participants. Cox models were used to assess baseline metabolites, interaction of metabolites and treatment group, and change in metabolites (0-36 months), with loss of glycemic control adjusted for age, sex, race, treatment group, and BMI. Metabolite prediction models of glycemic failure were generated using elastic net regression and compared with clinical risk factors. RESULTS: Loss of glycemic control (HbA1c ≥8% or insulin therapy) occurred in 179 of 393 participants (mean 12.4 months). Baseline levels of 33 metabolites were associated with loss of glycemic control (q < 0.05). Associations of hexose and xanthurenic acid with treatment failure differed by treatment randomization; youths with higher baseline levels of these two compounds had a lower risk of treatment failure with metformin alone. For three metabolites, changes from 0 to 36 months were associated with loss of glycemic control (q < 0.05). Changes in d-gluconic acid and 1,5-AG/1-deoxyglucose, but not baseline levels of measured metabolites, predicted treatment failure better than changes in HbA1c or measures of β-cell function. CONCLUSIONS: Metabolomics provides insight into circulating small molecules associated with loss of glycemic control and may highlight metabolic pathways contributing to treatment failure in youth-onset diabetes.
引用
- Chen ZZ, Lu C, Dreyfuss JM, et al. Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes. Diabetes Care. 2024. PMID: 38935559. doi:10.2337/dc23-2441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。